Core Viewpoint - The company forecasts a significant decline in net profit for the year 2025, primarily due to changes in market demand, increased competition, and rising operational costs associated with ongoing research and development efforts [2][5]. Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 41.3 million and 61.9 million yuan for 2025, representing a year-on-year decrease of 67.28% to 78.17% [2]. - The forecasted net profit, excluding non-recurring gains and losses, is projected to be between 4.3 million and 24.9 million yuan, indicating a year-on-year decline of 86.21% to 97.62% [2]. Previous Year Performance - In the previous year, the total profit was 157.2 million yuan, with a net profit attributable to shareholders of the parent company amounting to 189.2 million yuan [3]. - The net profit, excluding non-recurring gains and losses, was 180.5 million yuan [3]. Reasons for Performance Changes - The anticipated decline in net profit is attributed to fluctuations in influenza trends, changes in competitive landscape, and variations in customer demand, leading to reduced operating revenue and gross profit [5]. - Increased depreciation from completed construction projects and higher R&D expenses due to intensified investment in innovative drugs also contribute to the profit decrease [5]. Research and Development Progress - The company is focusing on the metabolic field and has developed a competitive product pipeline in multi-target combination therapies and innovative dosing frequencies [5]. - Key projects include: 1. BGM0504 injection for type 2 diabetes and weight loss, with ongoing clinical trials in China and the U.S. [5]. 2. Oral BGM0504 tablets, with IND applications approved in both China and the U.S. [6]. 3. BGM1812 injection, a new long-acting Amylin analog, currently in clinical trials in both countries [6][7]. 4. BGM1962, a novel long-acting selective receptor agonist, showing promising preclinical results [7]. 5. MSTN cyclic peptide injection, aimed at weight management while preserving lean body mass, currently in preclinical candidate stage [8]. 6. ALK7-targeted siRNA project, designed for obesity treatment, also in preclinical candidate stage [9].

Core Viewpoint - The company, Borui Biopharmaceuticals, anticipates a significant decline in its 2025 annual net profit, projecting a decrease of 67.28% to 78.17% compared to the previous year, primarily due to changes in market demand and increased R&D expenses [1][4]. Financial Performance Forecast - The estimated net profit attributable to the parent company for 2025 is projected to be between 41.3 million and 61.9 million yuan, representing a year-on-year decrease of 67.28% to 78.17% [1]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 4.3 million and 24.9 million yuan, reflecting a year-on-year decrease of 86.21% to 97.62% [1]. Previous Year Performance - In the previous year, the total profit was 157.2 million yuan, with a net profit attributable to the parent company of 189.2 million yuan, and a net profit after deducting non-recurring gains and losses of 180.5 million yuan [2]. Reasons for Performance Changes - The anticipated decline in net profit is attributed to several factors, including changes in flu trends, shifts in competitive landscape, fluctuations in customer demand, reduced operating income, increased depreciation from completed construction projects, and higher R&D expenses due to intensified investment in innovative drugs [4]. - The company is focusing on the metabolic field and has developed a competitive product pipeline in multi-target combination therapies and innovative dosing frequencies to provide comprehensive and personalized treatment options for patients [4]. Research and Development Progress - The company has made significant progress in its research projects, including: 1. BGM0504 injection for type 2 diabetes and weight loss, currently in Phase III clinical trials in China and undergoing regulatory processes in the U.S. and Indonesia [4]. 2. Oral BGM0504 tablets, with IND applications approved in both China and the U.S., currently in Phase I clinical studies [5]. 3. BGM1812 injection, a new long-acting Amylin analog, with ongoing Phase I clinical trials in both China and the U.S. [6]. 4. Oral BGM1812, in preclinical research, utilizing an authorized oral peptide formulation platform [7]. 5. BGM1962, a novel long-acting selective amylin receptor agonist, currently in preclinical research [8]. 6. MSTN cyclic peptide injection, aimed at weight management, currently in preclinical candidate stage [9]. 7. ALK7-targeted siRNA project, also in preclinical candidate stage, intended for obesity treatment [10].